STANDARD BIOTOOLS INC.
Close on Oct 19, 2026
- Market cap
- $251.45M
- P/E (TTM)
- 2.9
- Dividend yield
- –
About Standard Biotools
Pharmaceutical Preparations, SIC 2834
Standard BioTools Inc. provides life science tools and technologies designed to assist biomedical researchers in developing therapeutics. The company offers a portfolio of instrumentation, consumables, and laboratory services supporting multi-omic research across proteomics and genomics. Its core commercial platforms include CyTOF for single-cell mass cytometry, Hyperion for spatial biology and imaging mass cytometry, and Biomark for genomic analyses. These products enable scientists to analyze cellular functions, map tissue architectures, and explore disease mechanisms in areas such as oncology, immunology, and neurology.
The company operates internationally, serving customers across the Americas, Europe, the Middle East, Africa, and the Asia-Pacific region, with specific geographic exposure in countries such as the United States, Canada, China, Sweden, and Singapore. Standard BioTools maintains its principal executive offices in Boston, Massachusetts.
Summary of the business section of Standard Biotools's latest annual report, written by StockData.
Company profile
Company
- Legal name
- STANDARD BIOTOOLS INC.
- Founded
- 1999
- Headquarters
- Boston, MA
- Address
- 50 Milk Street, 10th Floor 02109
- Phone
- (650) 266-6000
- Website
- www.standardbio.com
- Employees
- 389, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers LLP, Irvine, California
Stock & identifiers
- Ticker
- LAB
- Exchange
- Nasdaq
- IPO date
- Feb 10, 2011
- Shares outstanding
- 393M, Aug 3, 2026
- Public float
- $290.90M, Jun 30, 2025
- Filer category
- Accelerated filer
- SEC CIK
- 1162194
- CUSIP
- 34385P108
- ISIN
- US34385P1084
- LEI
- 549300GX8Y96GSB6YP89
- EIN
- 77-0513190
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Michael Egholm | President & CEO, Director | 6,137,704 |
| Sean Mackay | SVP & Chief Business Officer | 1,480,823 |
| Hanjoon Alex Kim | Chief Financial Officer | 2,534,859 |
| Troy Cox | Director | 475,702 |
| Kathy L. Hibbs | Director | 236,836 |
| Frank Witney | Director | 314,203 |
| Eli Casdin | Director | 91,837,025 |
| Fenel M. Eloi | Director | 335,299 |
| Thomas D. Carey | Director | 344,456 |
| Casdin Private Growth Equity Fund II GP, LLC | Director | 11,496,255 |
| Casdin Partners GP, LLC | Director | 77,395,281 |
| Casdin Private Growth Equity Fund, L.P. | Director | 59,551,472 |
| Casdin Private Growth Equity Fund Gp, Llc | Director | 77,745,281 |
| Casdin Private Growth Equity Fund II, L.P. | Director | 57,301,472 |
| Casdin Partners Master Fund, L.P. | Director | 82,559,918 |
| Casdin Capital, LLC | Director | 61,653,250 |
| Casdin Amplify Fund, LP | Director | 58,551,472 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Dr Egholm | $8.82M | $6.20M | $2.85M | $21 | $125 |
| FY2025 Mr Linthwaite | $0 | $0 | $2.85M | $21 | $125 |
| FY2024 Dr Egholm | $8.34M | $3.79M | $2.72M | $29 | $93 |
| FY2024 Mr Linthwaite | $0 | $0 | $2.72M | $29 | $93 |
| FY2023 Dr Egholm | $1.93M | $6.17M | $1.23M | $37 | $94 |
| FY2023 Mr Linthwaite | $0 | $0 | $1.23M | $37 | $94 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had a total of 389 employees worldwide, excluding employees associated with our discontinued operations, of which 385 were full-time employees and 96 were located in the United States.”
Corporate history
Events identified from SEC filings